Hexarelin dosage: Frequently asked questions

Verify administration timing relative to meals. Hexarelin dosed within 90 minutes of carbohydrate or protein intake produces 40–60% lower GH peaks due to insulin-mediated somatostatin release. Confirm peptide reconstitution was performed correctly using bacteriostatic water and that the reconstituted solution has been stored at 2–8°C. If timing and storage are correct, increase dose incrementally from 100 mcg to 150 mcg per administration and reassess GH response (if direct GH measurement is available). Non-responders are rare but can occur in individuals with unusually high baseline somatostatin tone or pituitary GH reserve depletion.

Stacking hexarelin with GHRP-2, GHRP-6, or ipamorelin produces additive GH release in the short term but accelerates receptor desensitization across all GHS-R1a agonists simultaneously. Research from Peptides journal found that dual GHS protocols reduced individual peptide efficacy by week 3 compared to single-agent use. If stacking is pursued, consider pairing hexarelin with a GHRH analogue like CJC-1295 instead. GHRH works through a separate receptor pathway (GHRH-R) and produces synergistic rather than competitive effects.

No, but it complicates long-term adherence. Hexarelin's ghrelin receptor agonism triggers pronounced hunger in 40–60% of users, which can lead to caloric surplus and weight gain if unmanaged. Cardiovascular benefits are independent of appetite signaling, but obesity and metabolic syndrome counteract those gains systemically. Mitigation strategies: dose in the evening to shift appetite peak to sleep hours, pair with high-satiety foods (protein, fiber), or consider adjunct compounds like Tesofensine that suppress appetite through separate pathways.

Don't. Elevated insulin and glucose blunt GH secretion by 50–70% within the first 90 minutes post-meal. Wait minimum 2 hours after eating, 30 minutes before the next meal. If timing conflicts arise, skip the dose rather than administering it in a fed state. A missed dose is better than a wasted dose that triggers minimal GH release and still contributes to receptor desensitization.

Some individuals desensitize faster than the population average, particularly those with prior exposure to GH secretagogues or endogenous ghrelin dysregulation. If GH response declines noticeably before week 4, shorten the active phase to 3 weeks and extend the off-cycle to 3 weeks. Alternatively, reduce administration frequency from 3 times daily to 2 times daily. Receptor occupancy duration matters more than peak occupancy for desensitization rate.

This is expected receptor desensitization, not peptide degradation. Implement a 2–4 day washout immediately. During the break, GH secretory capacity recovers approximately 60–80% within 48 hours, near-complete recovery by 96 hours. Resume at the same dose after the washout. Do not increase dosage to compensate for reduced response, as higher doses accelerate desensitization further.

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Hexarelin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.